CRBP
Price
$5.70
Change
+$0.03 (+0.53%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
69.17M
STOK
Price
$6.53
Change
+$0.10 (+1.56%)
Updated
Apr 10, 04:59 PM (EDT)
Capitalization
347.18M
32 days until earnings call
Ad is loading...

CRBP vs STOK

Header iconCRBP vs STOK Comparison
Open Charts CRBP vs STOKBanner chart's image
Corbus Pharmaceuticals Holdings
Price$5.70
Change+$0.03 (+0.53%)
Volume$1.92K
Capitalization69.17M
Stoke Therapeutics
Price$6.53
Change+$0.10 (+1.56%)
Volume$24.59K
Capitalization347.18M
CRBP vs STOK Comparison Chart
Loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRBP vs. STOK commentary
Apr 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBP is a Hold and STOK is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 11, 2025
Stock price -- (CRBP: $5.66 vs. STOK: $6.42)
Brand notoriety: CRBP and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBP: 126% vs. STOK: 128%
Market capitalization -- CRBP: $69.17M vs. STOK: $347.18M
CRBP [@Biotechnology] is valued at $69.17M. STOK’s [@Biotechnology] market capitalization is $347.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $281.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBP’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • CRBP’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than CRBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBP’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • CRBP’s TA Score: 5 bullish, 3 bearish.
  • STOK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRBP is a better buy in the short-term than STOK.

Price Growth

CRBP (@Biotechnology) experienced а +8.75% price change this week, while STOK (@Biotechnology) price change was -2.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.53%. For the same industry, the average monthly price growth was -18.05%, and the average quarterly price growth was -19.90%.

Reported Earning Dates

CRBP is expected to report earnings on May 11, 2023.

STOK is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-7.53% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($347M) has a higher market cap than CRBP($69.2M). STOK YTD gains are higher at: -41.795 vs. CRBP (-52.076). CRBP has higher annual earnings (EBITDA): -37.75M vs. STOK (-115.03M). STOK has more cash in the bank: 239M vs. CRBP (149M). STOK has less debt than CRBP: STOK (2.3M) vs CRBP (3.24M). STOK has higher revenues than CRBP: STOK (16.7M) vs CRBP (0).
CRBPSTOKCRBP / STOK
Capitalization69.2M347M20%
EBITDA-37.75M-115.03M33%
Gain YTD-52.076-41.795125%
P/E RatioN/AN/A-
Revenue016.7M-
Total Cash149M239M62%
Total Debt3.24M2.3M141%
FUNDAMENTALS RATINGS
CRBP vs STOK: Fundamental Ratings
CRBP
STOK
OUTLOOK RATING
1..100
860
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
9591
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (33) in the null industry is in the same range as CRBP (55) in the Biotechnology industry. This means that STOK’s stock grew similarly to CRBP’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to CRBP’s over the last 12 months.

STOK's SMR Rating (94) in the null industry is in the same range as CRBP (95) in the Biotechnology industry. This means that STOK’s stock grew similarly to CRBP’s over the last 12 months.

STOK's Price Growth Rating (91) in the null industry is in the same range as CRBP (95) in the Biotechnology industry. This means that STOK’s stock grew similarly to CRBP’s over the last 12 months.

STOK's P/E Growth Rating (100) in the null industry is in the same range as CRBP (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to CRBP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRBPSTOK
RSI
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 25 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BROS60.407.81
+14.85%
Dutch Bros
TYRA7.900.84
+11.90%
Tyra Biosciences
GEO28.321.95
+7.39%
GEO Group (The)
BAC37.152.12
+6.05%
Bank of America Corp
ABOS1.060.01
+0.95%
Acumen Pharmaceuticals

CRBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with SKYE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then SKYE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBP
1D Price
Change %
CRBP100%
+4.92%
SKYE - CRBP
41%
Loosely correlated
+12.50%
APLS - CRBP
36%
Loosely correlated
+4.87%
FBIO - CRBP
36%
Loosely correlated
+1.75%
STOK - CRBP
33%
Loosely correlated
+8.81%
PMCB - CRBP
30%
Poorly correlated
+0.42%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with QTTB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
+8.81%
QTTB - STOK
49%
Loosely correlated
+14.48%
IDYA - STOK
47%
Loosely correlated
+8.69%
RNA - STOK
47%
Loosely correlated
+2.99%
RCKT - STOK
45%
Loosely correlated
+12.53%
DNLI - STOK
43%
Loosely correlated
+12.12%
More